Enhancement of anti-tumor immunity in immunogenic and immune-refractory RAS mutant tumors with tri-complex RAS(ON) inhibitors. (October 2022) - Blaj, C.; Menard, M.; Tobvis Shifrin, N.; Chen, K.; Chow, C.; Courtney, H.; Kumamoto, A.; Velilla, T.; Evans, J.W.; Lawrence, L.; Vonmelchert, B.; Kwok-Parkhill, A.; et al.